Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Vertex Pharmaceuticals    VRTX

VERTEX PHARMACEUTICALS

(VRTX)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
02/14/2019 02/15/2019 02/19/2019 02/20/2019 02/21/2019 Date
185.72(c) 188.07(c) 186.86(c) 187.84(c) 183.06(c) Last
917 789 1 408 240 1 823 670 1 066 275 1 086 953 Volume
+0.25% +1.27% -0.64% +0.52% -2.54% Change
More quotes
Financials (USD)
Sales 2019 3 570 M
EBIT 2019 1 394 M
Net income 2019 792 M
Finance 2019 4 637 M
Yield 2019 -
Sales 2020 4 512 M
EBIT 2020 2 181 M
Net income 2020 1 304 M
Finance 2020 4 952 M
Yield 2020 -
P/E ratio 2019 61,99
P/E ratio 2020 36,58
EV / Sales2019 11,8x
EV / Sales2020 9,27x
Capitalization 46 801 M
More Financials
Company
Vertex Pharmaceuticals specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales break down by type of income as follows: - income from sales of products (87%); - income from... 
More about the company
Surperformance© ratings of Vertex Pharmaceuticals
Trading Rating : Investor Rating :
More Ratings
Latest news on VERTEX PHARMACEUTICALS
02/21VERTEX PHARMACEUTICALS : Appoints Lloyd Carney to its Board of Directors
BU
02/15VERTEX PHARMACEUTICALS : Positive Phase 3 Study for Tezacaftor/Ivacaftor Combina..
AQ
02/14VERTEX PHARMACEUTICALS : Positive Phase 3 Study for Tezacaftor/Ivacaftor Combina..
BU
02/13VERTEX PHARMACEUTICALS : MA MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CO..
AQ
02/08VERTEX PHARMACEUTICALS : calls for changes to NICE as CF drug profits soar
AQ
02/05VERTEX : 4Q Earnings Snapshot
AQ
02/05VERTEX PHARMACEUTICALS INC / MA : Results of Operations and Financial Condition,..
AQ
02/05VERTEX PHARMACEUTICALS : Reports Full-Year and Fourth-Quarter 2018 Financial Res..
BU
02/01VERTEX PHARMACEUTICALS : Parliament to debate compulsory licensing of Vertex's O..
AQ
01/29MANAGEMENT TRACKS : Ironwood reveals board for new companies
AQ
More news
Analyst Recommendations on VERTEX PHARMACEUTICALS
More recommendations
Sector news : Bio Therapeutic Drugs
02/20GLOBAL MARKETS LIVE : Nissan, Lockheed Martin, UBS, Sainsbury...
02/12MARKET SNAPSHOT: Stocks Close At 2019 High On Tentative Deal To Avert Governm..
DJ
02/11Regeneron, Sanofi to Offer Praluent at Reduced U.S. List Price
DJ
02/11Sanofi and Regeneron cut list price of cholesterol drug by 60 percent
RE
02/06REGENERON PHARMACEUTICALS : 4Q Profit Rises
DJ
More sector news : Bio Therapeutic Drugs
Chart VERTEX PHARMACEUTICALS
Duration : Period :
Vertex Pharmaceuticals Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VERTEX PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 208 $
Spread / Average Target 13%
EPS Revisions
Managers
NameTitle
Jeffrey M. Leiden Chairman, President & Chief Executive Officer
Paul M. Silva Chief Financial Officer, Controller & Senior VP
David Matthew Altshuler Chief Scientific Officer & EVP-Global Research
Reshma Kewalramani Chief Medical Officer & Executive Vice President
Bruce I. Sachs Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
VERTEX PHARMACEUTICALS13.49%46 801
GILEAD SCIENCES6.73%86 647
REGENERON PHARMACEUTICALS13.51%45 363
GENMAB-5.57%9 415
SAREPTA THERAPEUTICS INC25.12%9 393
BLUEBIRD BIO INC38.14%7 298